China independently develops the first liver cancer targeted drug

, the Fourth Military Medical University in its exhibition of quality construction results announced that the university has successfully developed a national biological products with independent intellectual property rights of a new class of drug iodine (131I) metoxiatin synth (likatin)The drug is the world's first specific antibody specific ally for the treatment of liver cancer is also China's first full independent intellectual property rights, all new drug target sings oftumorantibody drugAt present, the drug has been listed nationwideThe incidence of liver cancer is dangerous, rapid progress, high mortality rate and poor treatment effectChinese mainland, Southeast Asia and Africa are the three regions with high incidence of liver cancer in the worldThe World Health Organization's annualHealthreport shows a liver cancer incidence rate of 23.7 per 100,000Globally, 620,000 people die of liver cancer each year (45 percent of china), only 11 percent of patients receive surgical treatment (20 percent reported in China) and have a high rate of recurrence after surgeryTherefore, the development of antibody-targeted drugs for the treatment of liver cancer is of great significanceIn 1987, Professor Chen Zhinan, director of the Cell Engineering Research Center of the Fourth Military Medical University, led a research group to develop antibody drugsFrom that year to obtain specific monoantibodies HAb18 fortumorsuch as liver cancer, they have overcome the antibody-specific screening, engineering cell preservation and sub-clone quality control, targeted antigen acquisition, antibody iodine labeling technology process, antibody in-test amplification and production process, antibody and marker quality control, antibody drug action principle research, antibody and marker preclinical research 8 key technologies And obtained the antibody light, heavy chain variable region gene and antigen amino acid sequence and other sources of key patents, established the metaxiatimonoic preparation, cell fermentation and other key production technology platform, as well as antibody applications and other 8 national invention patents and software copyright licensing, at the same time applied for two PCT international patents, in the Journal of Biochemistry, hepatology and other international well-known magazines published 40 SCI papers The research won the first prize of the military scientific and technological progress, the first prize of Shaanxi Province's scientific and technological progress, and the second prize of the national scientific and technological progress According to clinical experts, iodine .131I Studies have shown that the drug can be used as a first-line treatment of liver cancer in all stages of the drug or radiotherapy, chemotherapy drugs combined The clinical effectiveness rate of the drug was 27.4%, the clinical control rate was 86.3%, the 32-month survival rate (the long-term survival rate) reached 31.03 percent, and the effect of the anti-recurrence treatment of liver cancer was better (Lori Joan)